Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ECI2 divergent transcript (ECI2-DT) is a long non-coding RNA (lncRNA) gene, meaning its transcript does not encode a protein product. It is classified as an RNA gene affiliated with the lncRNA class, as indicated in gene resources. The term "divergent transcript" typically denotes a non-coding RNA transcribed from the genomic region adjacent to, and on the opposite DNA strand from, a protein-coding gene—in this case, the ECI2 gene (enoyl-CoA delta isomerase 2). There are currently no data supporting a direct biological function, disease relevance, or interaction with drugs for ECI2-DT. No evidence suggests it plays a role as a therapeutic target, receptor, enzyme, transporter, or any such actionable molecular entity. It most likely serves a regulatory RNA function in the context of genome transcription, but any distinct roles remain undefined. ECI2-DT is not the same as the protein-coding gene ECI2 (Enoyl-CoA delta isomerase 2), which is a mitochondrial enzyme involved in fatty acid metabolism. ECI2-DT is only an associated non-coding transcript and not a candidate for pharmacological targeting or direct therapeutic intervention. The term "divergent transcript" generally refers to non-coding RNAs produced by divergent transcription from promoters, often resulting in lncRNAs. ECI2-DT is catalogued in genomic databases as an lncRNA but lacks robust functional or disease-association data.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ECI2 divergent transcript (ECI2-DT).